euthasol vet. stungulyf, lausn 400 mg/ml
le vet b.v.* - pentobarbitalum natríum - stungulyf, lausn - 400 mg/ml
exagon vet. (exagon 400) stungulyf, lausn 400 mg/ml
vetviva richter gmbh - pentobarbitalum natríum - stungulyf, lausn - 400 mg/ml
phenoleptil tafla 100 mg
dechra regulatory b.v. - phenobarbitalum inn - tafla - 100 mg
phenoleptil tafla 25 mg
dechra regulatory b.v. - phenobarbitalum inn - tafla - 25 mg
dronedarone stada (verodron) filmuhúðuð tafla 400 mg
stada arzneimittel ag - dronedaronum hýdróklóríð - filmuhúðuð tafla - 400 mg
actrapid
novo nordisk a/s - mannainsúlín - sykursýki - lyf notuð við sykursýki - meðferð sykursýki.
actraphane
novo nordisk a/s - insulin human - sykursýki - lyf notuð við sykursýki - meðferð sykursýki.
mixtard
novo nordisk a/s - insulin human - sykursýki - lyf notuð við sykursýki - meðferð sykursýki.
benestermycin vet. spenalyf, smyrsli
boehringer ingelheim vetmedica gmbh* - framycetinum súlfat; benethaminum penicillinum inn; penethamate hydroiodide ban - spenalyf, smyrsli
dasatinib accord
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - Æxlishemjandi lyf - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.